Skip to Content
Uncategorized

Nuts to That

Severe, even life-threatening peanut allergies afflict 3 million people in the United States alone. The only protection now available is to avoid peanuts and their derivatives. While it’s easy to eschew peanut butter sandwiches, who’s to know if the chips at the office party were fried in peanut oil? Houston-based Tanox has begun human testing of a once-a-month injection to protect the peanut-averse from accidental exposure. The drug, Hu-901, is an antibody that blocks the immune reaction responsible for swelling and itching. People taking it probably won’t be able to eat nuts daily, but they should have more time to get help if they do eat those chips.

If Hu-901 is effective in preventing peanut allergies, Tanox may investigate its use against other food allergies. The company hopes a similar antibody to treat seasonal allergies and asthma will get regulatory approval by mid-2001.

Deep Dive

Uncategorized

Our best illustrations of 2022

Our artists’ thought-provoking, playful creations bring our stories to life, often saying more with an image than words ever could.

How CRISPR is making farmed animals bigger, stronger, and healthier

These gene-edited fish, pigs, and other animals could soon be on the menu.

The Download: the Saudi sci-fi megacity, and sleeping babies’ brains

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. These exclusive satellite images show Saudi Arabia’s sci-fi megacity is well underway In early 2021, Crown Prince Mohammed bin Salman of Saudi Arabia announced The Line: a “civilizational revolution” that would house up…

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.